21 results
Keyword Alemtuzumab Remove keyword
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Lemtrada
alemtuzumab, Multiple Sclerosis
Date of authorisation: 12/09/2013,
, Revision: 7, Authorised
Lemtrada INN-alemtuzumab 30 Churchill Place … for the public Lemtrada alemtuzumab This is a summary of the … contains the active substance alemtuzumab. How is Lemtrada used … -
List item
Human medicine European public assessment report (EPAR): MabCampath
alemtuzumab, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 06/07/2001, Revision: 14, Withdrawnstatement on MabCampath (alemtuzumab): Withdrawal of the marketing … Public statement MabCampath (alemtuzumab) Withdrawal of the marketing … medicinal product MabCampath (alemtuzumab) for the treatment of patients … -
List item
Human medicine European public assessment report (EPAR): Arzerra
ofatumumab, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 19/04/2010,
, Revision: 16, Authorised
fludarabine and a medicine called alemtuzumab; • in patients whose disease … to both fludarabine and alemtuzumab, and in 112, treatment with … had not been treated with alemtuzumab because this medicine was … -
List item
Human medicine European public assessment report (EPAR): Gilenya (updated)
fingolimod hydrochloride , Multiple Sclerosis
Date of authorisation: 17/03/2011,
, Revision: 22, Authorised
-
List item
Human medicine European public assessment report (EPAR): Zessly
infliximab, Arthritis, Psoriatic, Psoriasis, Crohn Disease, Arthritis, Rheumatoid, Colitis, Ulcerative, Spondylitis, Ankylosing
Date of authorisation: 18/05/2018,, 
, Revision: 2, Authorised
-
List item
Human medicine European public assessment report (EPAR): Torisel
Temsirolimus, Carcinoma, Renal Cell, Lymphoma, Mantle-Cell
Date of authorisation: 19/11/2007,, Revision: 29, Authorised
-
List item
Human medicine European public assessment report (EPAR): Prevymis
Letermovir, Cytomegalovirus Infections
Date of authorisation: 08/01/2018,, , Revision: 2, Authorised
-
List item
Human medicine European public assessment report (EPAR): Ocrevus
ocrelizumab, Multiple Sclerosis
Date of authorisation: 08/01/2018,, Revision: 3, Authorised
-
List item
Human medicine European public assessment report (EPAR): Gazyvaro
Obinutuzumab, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 22/07/2014,, , Revision: 7, Authorised
-
List item
Human medicine European public assessment report (EPAR): Venclyxto
Venetoclax, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 04/12/2016,, 
, Revision: 7, Authorised
-
List item
Human medicine European public assessment report (EPAR): Cosentyx
Secukinumab, Arthritis, Psoriatic, Psoriasis, Spondylitis, Ankylosing
Date of authorisation: 14/01/2015,, Revision: 11, Authorised
-
List item
Human medicine European public assessment report (EPAR): Imbruvica
Ibrutinib, Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 21/10/2014,, , Revision: 12, Authorised
-
List item
Human medicine European public assessment report (EPAR): Tysabri
natalizumab, Multiple Sclerosis
Date of authorisation: 27/06/2006,, Revision: 27, Authorised
-
List item
Human medicine European public assessment report (EPAR): Mavenclad
Cladribine, Multiple Sclerosis
Date of authorisation: 22/08/2017, Revision: 2, Authorised -
List item
Human medicine European public assessment report (EPAR): Zydelig
Idelalisib, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 18/09/2014,, Revision: 14, Authorised
-
List item
Human medicine European public assessment report (EPAR): Revolade
Eltrombopag olamine, Purpura, Thrombocytopenic, Idiopathic
Date of authorisation: 11/03/2010,, Revision: 21, Authorised
-
List item
Human medicine European public assessment report (EPAR): Zinbryta
daclizumab, Multiple Sclerosis
Date of authorisation: 01/07/2016,, , Revision: 8, Withdrawn
-
List item
Human medicine European public assessment report (EPAR): Erelzi
etanercept, Arthritis, Psoriatic, Psoriasis, Arthritis, Juvenile Rheumatoid, Arthritis, Rheumatoid, Spondylitis, Ankylosing
Date of authorisation: 23/06/2017,, , Revision: 3, Authorised
-
List item
Human medicine European public assessment report (EPAR): Nerventra
laquinimod, Multiple Sclerosis
Date of refusal: 19/08/2014, Refused -
List item
Human medicine European public assessment report (EPAR): Istodax
romidepsin, Lymphoma, Non-Hodgkin
Date of refusal: 12/02/2013,, Refused
-
List item
Human medicine European public assessment report (EPAR): Folotyn
Pralatrexate, Lymphoma, T-Cell
Date of refusal: 21/06/2012,, Refused